{"id":16029,"date":"2014-03-13T13:50:36","date_gmt":"2014-03-13T18:50:36","guid":{"rendered":"http:\/\/cmeded.wpengine.com\/?page_id=16029"},"modified":"2023-08-24T18:48:37","modified_gmt":"2023-08-24T23:48:37","slug":"staging","status":"publish","type":"page","link":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/","title":{"rendered":"Estadificaci\u00f3n"},"content":{"rendered":"<h4 class=\"section-title\">Estadificaci\u00f3n<\/h4>\n<p class=\"section-content\">En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda.  Los m\u00e9dicos clasifican la LMA en funci\u00f3n de si no est\u00e1 tratada, si est\u00e1 en remisi\u00f3n o si es recidivante.<\/p>\n<div class=\"clapat-tabs\" id=\"aml\"><div class=\"tabs-bg\"><\/div><ul class=\"staging-tab-menu\"><li><a href=\"#tabs-560\"><br \/>\nNo tratada<\/a><\/li>\n<li><a href=\"#tabs-561\"><br \/>\nEn remisi\u00f3n<\/a><\/li>\n<li><a href=\"#tabs-562\"><br \/>\nRecidivante<\/a><\/li><\/ul><div class=\"list-wrap\"><div id=\"tabs-560\"><\/p>\n<h4 class=\"section-title hidden-title\">No tratada<\/h4>\n<p><div id=\"stage\" style=\"width: 268px\" class=\"wp-caption alignnone\"><a href=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/AML-myeloblast-cells-es.jpg\" title=\"Click Image to Enlarge.\"><img decoding=\"async\" aria-describedby=\"caption-stage\" src=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/AML-myeloblast-cells-es.jpg\" alt=\"No tratada\" class=\"aligncenter\" style=\"max-height:185px;\"\/><\/a><p id=\"caption-stage\" class=\"wp-caption-text\">Click Image to Enlarge.<\/p><\/div><\/p>\n<h5 class=\"section-title\">Descripci\u00f3n<\/h5>\n<ul>\n<li class=\"section-content\">La LMA no tratada incluye a todos los pacientes reci\u00e9n diagnosticados que a\u00fan no se sometieron a un tratamiento.  Estos pacientes pueden presentar un hemograma anormal, as\u00ed como signos y s\u00edntomas de LMA.  Alrededor del 20 % de las c\u00e9lulas de la m\u00e9dula \u00f3sea o sangre del paciente son blastocitos.<\/li>\n<\/ul>\n<h5 class=\"section-title\">Tratamiento<\/h5>\n<ul>\n<li class=\"section-content\">Quimioterapia, quimioterapia de dosis alta con trasplante de c\u00e9lulas madre.<\/li>\n<\/ul>\n<hr class=\"hidden-title\"\/>\n<\/div>\n<div id=\"tabs-561\"><\/p>\n<h4 class=\"section-title hidden-title\">En remisi\u00f3n<\/h4>\n<p><div id=\"stage-2\" style=\"width: 269px\" class=\"wp-caption alignnone\"><a href=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/AML-normal-cells-es.jpg\" title=\"Click Image to Enlarge.\"><img decoding=\"async\" aria-describedby=\"caption-stage-2\" src=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/AML-normal-cells-es.jpg\" alt=\"En remisi\u00f3n\" class=\"aligncenter\" style=\"max-height:185px;\"\/><\/a><p id=\"caption-stage-2\" class=\"wp-caption-text\">Click Image to Enlarge.<\/p><\/div><\/p>\n<h5 class=\"section-title\">Descripci\u00f3n<\/h5>\n<ul>\n<li class=\"section-content\">Esto incluye a todos los pacientes que han realizado tratamientos y por lo cual el c\u00e1ncer se encuentra en remisi\u00f3n. Para que se considere que el c\u00e1ncer est\u00e1 en remisi\u00f3n, el paciente debe presentar un hemograma normal y ausencia de s\u00edntomas; adem\u00e1s, la m\u00e9dula \u00f3sea del paciente debe tener menos de un 5 % de blastocitos.<\/li>\n<\/ul>\n<h5 class=\"section-title\">Tratamiento<\/h5>\n<ul>\n<li class=\"section-content\">Quimioterapia combinada, quimioterapia de dosis alta con trasplante de c\u00e9lulas madre con radioterapia o sin ella.<\/li>\n<\/ul>\n<hr class=\"hidden-title\"\/>\n<\/div>\n<div id=\"tabs-562\"><\/p>\n<h4 class=\"section-title hidden-title\">Recidivante<\/h4>\n<p><div id=\"stage-3\" style=\"width: 272px\" class=\"wp-caption alignnone\"><a href=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/AML-myeloblast-cells-es.jpg\" title=\"Click Image to Enlarge.\"><img decoding=\"async\" aria-describedby=\"caption-stage-3\" src=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/AML-myeloblast-cells-es.jpg\" alt=\"Recidivante\" class=\"aligncenter\" style=\"max-height:185px;\"\/><\/a><p id=\"caption-stage-3\" class=\"wp-caption-text\">Click Image to Enlarge.<\/p><\/div><\/p>\n<h5 class=\"section-title\">Descripci\u00f3n<\/h5>\n<ul>\n<li class=\"section-content\">La LMA recidivante incluye a todos los pacientes en los que el c\u00e1ncer volvi\u00f3 a aparecer despu\u00e9s de la etapa de remisi\u00f3n. Estos pacientes tienen otras perspectivas y requieren tratamientos diferentes de los que se indican para los pacientes reci\u00e9n diagnosticados.<\/li>\n<\/ul>\n<h5 class=\"section-title\">Tratamiento<\/h5>\n<ul>\n<li class=\"section-content\">Quimioterapia combinada, terapia dirigida, quimioterapia de dosis alta con trasplante de c\u00e9lulas madre y estudios cl\u00ednicos.<\/li>\n<\/ul>\n<hr class=\"hidden-title\"\/>\n<\/div><\/div><\/div>\n<div class=\"clearboth\"><\/div>\n<div class=\"space\" style=\"clear:both; height:25px;\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n de si no est\u00e1 tratada, si est\u00e1 en remisi\u00f3n o si es recidivante.<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":16018,"menu_order":5,"comment_status":"closed","ping_status":"open","template":"template-tumor.php","meta":{"footnotes":""},"tags":[10],"class_list":["post-16029","page","type-page","status-publish","hentry","tag-members-only"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CMedEd | Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA) | Estadificaci\u00f3n<\/title>\n<meta name=\"description\" content=\"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CMedEd | Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA) | Estadificaci\u00f3n\" \/>\n<meta property=\"og:description\" content=\"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/\" \/>\n<meta property=\"og:site_name\" content=\"CMedEd\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T23:48:37+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/\",\"url\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/\",\"name\":\"CMedEd | Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA) | Estadificaci\u00f3n\",\"isPartOf\":{\"@id\":\"https:\/\/cmeded.com\/es\/#website\"},\"datePublished\":\"2014-03-13T18:50:36+00:00\",\"dateModified\":\"2023-08-24T23:48:37+00:00\",\"description\":\"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n\",\"breadcrumb\":{\"@id\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cmeded.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leucemia\",\"item\":\"https:\/\/cmeded.com\/es\/leukemia\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA)\",\"item\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Estadificaci\u00f3n\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cmeded.com\/es\/#website\",\"url\":\"https:\/\/cmeded.com\/es\/\",\"name\":\"CMedEd\",\"description\":\"Recurso principal de informaci\u00f3n sobre el c\u00e1ncer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cmeded.com\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CMedEd | Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA) | Estadificaci\u00f3n","description":"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/","og_locale":"es_ES","og_type":"article","og_title":"CMedEd | Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA) | Estadificaci\u00f3n","og_description":"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n","og_url":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/","og_site_name":"CMedEd","article_modified_time":"2023-08-24T23:48:37+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/","url":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/","name":"CMedEd | Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA) | Estadificaci\u00f3n","isPartOf":{"@id":"https:\/\/cmeded.com\/es\/#website"},"datePublished":"2014-03-13T18:50:36+00:00","dateModified":"2023-08-24T23:48:37+00:00","description":"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia mieloide aguda. Los m\u00e9dicos clasifican la LMA en funci\u00f3n","breadcrumb":{"@id":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/staging\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cmeded.com\/es\/"},{"@type":"ListItem","position":2,"name":"Leucemia","item":"https:\/\/cmeded.com\/es\/leukemia\/"},{"@type":"ListItem","position":3,"name":"Informaci\u00f3n para comprender la leucemia mieloide aguda (LMA)","item":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-myeloid-leukemia-aml\/"},{"@type":"ListItem","position":4,"name":"Estadificaci\u00f3n"}]},{"@type":"WebSite","@id":"https:\/\/cmeded.com\/es\/#website","url":"https:\/\/cmeded.com\/es\/","name":"CMedEd","description":"Recurso principal de informaci\u00f3n sobre el c\u00e1ncer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cmeded.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages\/16029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/comments?post=16029"}],"version-history":[{"count":0,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages\/16029\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages\/16018"}],"wp:attachment":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/media?parent=16029"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/tags?post=16029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}